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1. INTRODUCTION  
 
In the last twenty years, antiviral therapy with nucleo(s)tide 
analogues (NA) has considerably changed the natural 
history of chronic liver disease in patients affected by chronic 
HBV infection. Before NA therapy the main cause of 
morbidity and mortality was decompensated liver disease 
(LD) followed by hepatocellular carcinoma (HCC) 
(Fattovich 2003).  
Therefore the antiviral therapy improved the overall free 
survival and LD and HCC free survival patients. So it  
reduced HCC risk from 30% to 80%.	Many studies revealed 
that patients treated with third generation NA, which are 
entecavir and tenofovir, have an HCC annual risk 
development ranging from 0.5% to 1.4%. These patients 
have not cirrhosis and they are treatment naïve. This risk is 
increased instead in patients with liver cirrhosis and 
treatment-naive varying from 0.9% to 5.4.	
(Papatheodoridis, Chan et al. 2015). These data confirm 
previous data about the first generation NA in which the HCC 
annual risk ranged from 1.5% (Liaw, Sung et al. 2004) to  
2.5% (Papatheodoridis, Manolakopoulos et al. 2011). 
Thus Antiviral therapy has changed the natural history of 
 5 
liver disease through a chronic HBV infection modification. 
This modification involves HBeAg seroconversion and a 
level of HBV-DNA under the lower limit of detection. 
However, patients with chronic hepatitis and cirrhosis still  
have a residual risk of HCC development. For this reason it 
is necessary to identify risk factors and predictors of HCC 
that can not be modified by antiviral therapy but which may 
contribute to the development of HCC. 																								
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2. OBJECTIVE 
 
The objective of this study is to evaluate in a population of 
patients, consecutively followed at Gastroenterology Unit, 
affected by chronic HBV infection and clinical or biopsy 
diagnosis of chronic hepatitis and/or liver cirrhosis:  
- the liver complications incidence (liver decompensation, 
HCC and death) 
- not editable factors by antiviral therapy but which are 
responsible for HCC development. These are: 
a) polimorphism SNPs of MerTK gene. Recently a 
genome wide association study identifies MERTk as 
responsible for fibrosis worsening (Patin, Kutalik et al. 
2012). MerTK is a tyrosine kinase receptor of the TAM 
(Tyro3, Axl, MERTK) family, which is overexpressed or 
ectopically expressed in a wide variety of cancers. This 
receptor is expressed in macrophages particularly in M2 
which are responsible for oncogenesis (Sica, Invernizzi et 
al. 2014).  
b) HBsAg levels serum (qHBsAg). A study conducted on 
not treated Asiatic patients HBeAg negative with genotype 
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B and HBV-DNA < 2.000 IU/mL, showed that qHBsAg levels 
serum > 1.000 IU/mL are an indipendent risk factor for HCC 
development. However it is not yet known the behavior of 
this indicator during antiviral therapy with NA (Tseng, Liu et 
al. 2012). 
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3. PATIENTS AND METHODS 
       Patients. It was evaluated a cohort of patients infected 
by chronic HBV consecutively followed from 1996 to 2015 in 
Gastroenterology Unit of Policlinico Universitario P. 
Giaccone of Palermo. 248 of 443 patients with chronic HBV 
infection were evaluated. These patients had an histological  
and/or clinical diagnosis of HBV chronic hepatitis and liver 
cirrhosis. They were treated from the time of diagnosis, with 
antiviral therapy with nucleos(t)ide analogs, according to the 
International guidelines (EASL) (European Association For 
The Study Of The 2012) with  lamivudine, adefovir dipivoxil, 
entecavir, tenofovir disoproxil, telbivudina, monotherapy or 
in association therapy  in those patients with viral mutations. 
The treatment’s objective was achieving virological 
suppression (HBV DNA <20 IU / ml). Patients affected by 
hepatocellulare carcinoma diagnosis, HCV and HIV 
coinfection at presentation were excluded from the study. 
       Methods. Chronic HBV infection was defined by 
presence of HBsAg positivity to at least six months and with 
HBV-DNA over the normal range > 20 UI/ml according to 
COBAS® TaqMan® HBV Test v2.0, an in vitro nucleic acid 
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amplification for quantification of hepatitis B virus DNA on 
the serum or plasma and with linear range between 20 
IU/mL e 170.000.000 IU/mL. The virological (HBV-DNA, 
HBeAg, anti-HBe) and biochemical parameters 
(transaminases, bilirubin, Quick Time, complete blood 
count, creatinine) were assessed before treatment and 
during it every of 3- 4 months. In those patients in which it 
was found an increase of the levels of viremia  at least 1 
log10 during the treatment, HBV polymerase gene was 
sequenced to detect the mutation (spontaneous or induced 
by the therapy) able to identify the resistance to antivirals 
therapy.  After extraction, the HBV-DNA genome was 
purified and subjected to PCR to amplify the Pol gene. 
The product obtained was subjected to automated 
sequencing, and the nucleotide sequences analyzed in 
order to search for specific mutations. This method has a 
sensitivity of 15 IU / mL. It was evaluated also the presence 
the coinfection HCV and HDV.  The virological evaluation 
included quantitative HCV-RNA by reverse transcription-
PCR using Cobas Amplicor HCV Monitor Test, v 2.0; Roche, 
Basel, Switzerland, and HCV genotyping by INNO-LiPA 
HCV II assay; Innogenetics, Zwijndrecht, Belgium), IgG and 
IgM againts HDV and HDV-RNA. 
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In all patients HCC was surveilled through abdomen 
ultrasound and AFP dosage every 6 months. The HCC 
diagnosis and staging was performed on histological or 
radiological criteria, according to current EASL 
guidelines(European Association For The Study Of The 
Liver et al. 2012). Since the virological suppression time 
patients was followed every 3-4 months  keeping HBV-DNA 
under normal limit to the last evaluation: in patients who 
don’t develop HCC is the last clinical evaluation avaiable; 
while in patients who develop HCC is the HCC diagnosis 
time. In patients with clinical and histological cirrhosis 
diagnosis and small esophageal varices, an upper 
gastrointestinal endoscopy was performed every 1-2 years. 
The patients with large esophageal varices (> F2) were 
treated with beta-blockers or  elastic band ligation according 
to the guidelines of BAVENO (de Franchis and Baveno 
2015).  
 
qHBsAg level serum quantification  
HBsAg level serum was performed at the time of virological 
suppression and at the last clinical evaluation. This last 
evaluation in those patients affected by HCC coincides with 
the time of HCC development, while inthose patients without 
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HCC is the last evaluation available. The HBsAg was 
quantified by the ARCHITECT method (sensitivity of ≤ 0.05 
IU / mL.), which is an immunoassay of microparticles coated 
with anti-HBs by chemioilluminescenz designed to detect 
HBsAg. 
 
Polimorphism SNPs MerTK gene determination 
The DNA will be extracted out of the column using the 
chromatography affinity principle via QIAamp DNA Mini and 
Blood Mini Kit (Qiagen) or QIAamp Circulating nucleic acid 
kit (Qiagen). The yield and integrity of the DNA is tested by 
measuring optical density with a spectrophotometer UV 
(260/280 nm ratio <2) and by electrophoresis on agarose 
gel. The genotyping study of polymorphism (rs4374383) is 
performed in real-time PCR assays for allelic discrimination 
with TaqMan probes containing allele-specific markers such 
as fluorochromes FAM or VIC, which allow the operator you 
to highlight the two variants in any single nucleic acid 
sequence. If this method is not designed to efficiently reveal 
allelic variants (regions too rich CG) it is applied to the 
Sanger method of direct sequencing 
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Statistical Analisys  
All data were analyzed using the statistical package SPSS 
(version 20.0; SPSS, Chicago, IL, USA). Continuous 
variables were summarized as mean and standard deviation 
(S.D.), and categorical variables as frequency and 
percentage. The differences between media and median are 
evaluated with t Student, chi Square and Fisher test. 
Correlation between variables was evaluated by Spearman 
correlation. Significance testing was two sided and set to < 
0.05. Logistic regression analysis was used to determine 
independent associations with the presence of liver disease 
at baseline. Cox regression analysis was used to evaluate 
the variables associated with HCC occurrence during the 
follow-up. HCC was defined as one or more nodule in the 
liver with particular contrast enhancement. The baseline 
variables included in the analysis to determine the 
association with the presence of HCC were age, gender, 
HBeAg status, HDV status, HBV-DNA log, oesophageal 
varices and MERk and the variables included in the Cox 
analysis to determine the association with the HCC were 
age, gender, HBeAg status, HDV status, OV and MERTk 
SNPs. The proportion of patients who experienced HCC and 
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the time of the event were evaluated by Kaplan-Meier curves 
and log-rank analysis. A comparison between MERTk value 
in patients who developed HCC and those who died during 
follow-up was performed.		Area under the receiver operating 
characteristic (AUROC) analysis was used to establish the 
best cut off value of qHBsAg to predict the presence of HCC. 
Sensitivity (Se), specificity (Sp), positive and negative pre-
dictive values (PPV and NPV), positive likelihood ratio (+LR) 
and negative likelihood ratio (-LR) were calculated using cut-
offs resulting in a diagnosis of HCC. Logistic regression 
analysis was used to determine independent associations 
with the qHBsAg at baseline.  
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4. RESULTS 
 
 
Four hundred forty three patients with clinical or histological 
diagnosis of chronic hepatitis B or cirrhosis  (244 chronic 
hepatitis and 170 cirrhosis) were included in the study 
between 1996 to 2015. Only two hundrend forty eight 
patients, of which 134 (54%) with chronic hepatitis, and 114 
(46%) with chirrosis, were administrated third generation 
antiviral therapy with NA (41,9%),  31% TDV, 69% ENT. 
They maintained a constant viral suppression under 
detectable limit (HBV DNA <20 IU/ml). 
There are not  statistically significant differences between 
the two groups in terms of sex, therapeutic and virological 
factors. The only difference between the two groups was the 
age of patients. Indeed the patients with cirrhosis are older 
than patients with chronic hepatitis (TABLE 1).  
Among 248 patients with virologic suppression 222 (89.5%) 
did not develop HCC, while the other 26 (10%) developed 
HCC (TABLE 2). 
Kaplan-Meier curve-analisys demonstrate that patients with 
HBV liver cirrhosis have an increased risk of developing 
HCC than patients with chronic hepatitis (p <0.0001 by log 
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rank test) with 2.9% annual incidence versus 0.5% of 
patients with chronic hepatitis (FIGURE 1). 
Also Kaplan-Meier curves-analisys show that patients with 
cirrhosis have a higher risk to develope liver 
decompensation (p = 0.0002 by log rank test) and death 
related to liver disease (p <0.0001 by log rank test) than 
patients with chronic hepatitis (FIGURE 2 and 3). There is 
not difference in terms of HBsAg seroconversion (FIGURE 
4) 
 
rs4374383 SNP of MerTK gene as a predictor of 
hepatocellular carcinoma 
Cox-multivariate analysis demonstrate that the 
hepatocellular carcinoma related factors are cirrhosis (HR 
4.17 (1.11 - 15.67) p 0.03), esophageal varices (HR 2.73 
(1:14 to 6:53) p 0.02) and MerTK (HR 00:34 (0:13 - 0.93) p 
0.03) (TABLE 3). AG or AA genotype of polimorphism 
rs4374383 SNP of MerTK gene represents an additional risk 
for the development of hepatocellular carcinoma as 
demonstrated by the Kaplan-Meier curve-analisys (FIGURE 
5). 
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qHBsAg level serum as a predictor of hepatocellular 
carcinoma 
The analysis of qHBsAg serum was conducted in 75 of 114 
patients with HBV liver cirrhosis, which were HBeAg 
negative.These qHBsAg was evaluated at the time of 
virological suppression and at the of hepatocellular 
carcinoma development in patients who develop HCC (9 
patients 22%) and at the last clinical assessment available, 
for patients without HCC in 66 patients (88%). The analysis 
showed that the only parameter that differentiates the two 
groups is given by the serum HBsAg during the development 
of hepatocellular carcinoma, in both univariate and 
multivariate analysis (AdjustedHR (95% CI) p 1.003 (1.000-
1.005) 0.047) (TABLE 4). There is a strong correlation with 
serum levels at the time of virologic suppression (r2 = 0.525, 
p = <0.001) evident on linear regression. Among the 
patients, who develop HCC it was also demonstrated a 
notable increase of qHBsAg serum levels (FIGURE 6). The 
qHBsAg better cut-off obtained using reciving operated 
curve, ROC curve, is 3098.38 IU/ml with an AUROC 0.562, 
a sensitivity of 50%, specificity of 89%, a PPV 89% and NPV 
51% and an LR + 4.64 and LR- 0.56. So using the qHBsAg 
with the cut-off of 3098.38 IU/ml, it is possible to identify 
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patients with higher risk of HCC as shown by the survival 
curves according to Kaplan-Maier (Log rank test p: 0.005) 
(FIGURE 7). 
 
 
5. DISCUSSION 
 
Preliminary data conducted in a population of patients with 
chronic HBV infection with constant virological (HBV DNA 
<20 IU/ml) and biochemical (ALT value persistently normal) 
suppression by nucleo(s)tide antiviral therapy, show that in 
patients with compensated liver cirrhosis there is a residual 
risk to develop hepatocellular carcinoma. This risk seems to 
be independent by virological factors directly editable from 
antiviral therapy. The qHBsAg is a good diagnostic test to 
predict the hepatocellular carcinoma development in 
patients with virologic suppression. The progressive 
increase associated with values over 3000 IU/ml can identify 
patients with a high risk for HCC development. 
Polymorphism rs4374383 SNP in the gene MerTK and in 
particular the AA and AG genotypes confer an additional risk 
to develop HCC among patients with chronic HBV infection 
and particularly among those with liver cirrhosis. 
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These data on one hand identify the possible risk factors of 
HCC among patients with HBV, while on the other hand can 
help to identify patients at risk to improve clinical 
surveillance and ultrasound HCC. However there are still 
open issues about HCC in patients with chronic HBV 
infection which are the timing of the assessment and 
evaluation of qHBsAg and the biomolecular mechanisms 
responsible for HCC. 
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6. TABLES AND FIGURES 
 
TABLE 1. Baseline features according to stage disease in patients with chronic 
HBV infection under antiviral therapy.  
 
 
 
 
 
 
 
 
 
 20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABELLA 2. Clinical events according to stage disease during antiviral 
therapy. 
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FIGURE 1. HCC developement risk according to stage disease. 
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FIGURE 2. Liver decompensation risk according to stage disease during 
antiviral therapy  
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FIGURE 3. Survival analisys according to stage disease 
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FIGURE 4. HBsAg seroconversion probability according to stage disease  
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TABLE 3. Risk factors for Hepatocellular Carcinoma (HCC)  by Cox 
multivariate model 
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FIGURE 5. Hepatocellular Carcinoma risk according to stage disease and 
rs4374383 SNP of MerTK gene  
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TABLE 4. Risk factors associated with HCC developement in patients with 
HBV cirrhosis and HBsAg evaluation  
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FIGURE 6. Box-plot dei livelli sierici di qHBsAg in relazione allo sviluppo di 
epatocarcinoma 
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FIGURE 7. HCC risk according to qHBsAg serum levels with cut-off 3000 
UI/ml 
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